Cipla to further invest Rs 42 crore in GoApptiv

Published On 2023-12-15 08:00 GMT   |   Update On 2023-12-15 12:17 GMT

Mumbai: Cipla Limited has announced that it has agreed to further invest Rs 42 crore (approx.) in digital tech company GoApptiv Private Limited.This development will further expand Cipla’s presence across the healthcare continuum, especially to the underserved population by enabling greater access to lifesaving treatments. With the completion of this deal, Cipla’s total stake in...

Login or Register to read the full article

Mumbai: Cipla Limited has announced that it has agreed to further invest Rs 42 crore (approx.) in digital tech company GoApptiv Private Limited.

This development will further expand Cipla’s presence across the healthcare continuum, especially to the underserved population by enabling greater access to lifesaving treatments.

With the completion of this deal, Cipla’s total stake in GoApptiv will increase to 22.99% on a fully diluted basis. This is Cipla’s third investment in GoApptiv, which will be made in a combination of equity shares and compulsorily convertible preference shares.

GoApptiv has experienced significant expansion in underpenetrated areas and product lines following prior investments by Cipla in 2022 and 2020.

Commenting on the development, Umang Vohra, MD and Global CEO, Cipla Limited, said, “Our long-standing partnership with GoApptiv has helped us increase penetration in underserved rural areas of India and address critical healthcare gaps where pharmaceutical coverage is limited. In this era of technology-driven healthcare, this expanded investment will help us deliver patient-centric solutions and further strengthen our digitisation agenda to drive Cipla’s next phase of growth.”

Read also: Submit Justification to study Tocilizumab in patients with giant cell arteritis: CDSCO Panel Tells Cipla

"The current investment round will further solidify the partnership with Goapptiv in addressing healthcare disparities in underserved regions of India," Cipla stated.

Read also: Cipla reports bigger-than-expected rise in Q2 profit

Cipla Limited is an Indian multinational pharmaceutical and biotechnology company headquartered in Mumbai, India. Khwaja Abdul Hamied founded the Company in 1935 in Mumbai. Cipla has extended its presence to 80+ countries providing over 1,500 products across various therapeutic categories in 50+ dosage forms. The Company is also deepening its presence in the key markets of India, South Africa, the U.S. among other economies of the emerging world.   
Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News